ArticleExperimental and therapeutic medicine2026
Mechanism of microRNA-30b-5p enhancing the response of MDA-MB-231 cells to cisplatin by regulating RAP1B expression.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigated the role of hsa-microRNA (miR)-30b-5p in potentiating cisplatin-induced cytotoxicity in triple-negative breast cancer (TNBC) MDA-MB-231 cells via Ras-related protein Rap-1b (RAP1B) regulation. Expression levels of hsa-miR-30b-5p and RAP1B were examined in multiple breast cell lines, including normal breast epithelial cells (MCF-10A) and breast cancer cell lines (MCF-7, MDA-MB-231 and MDA-MB-468). MDA-MB-231 cells were divided into control, miR-30b-5p mimic, cisplatin (DDP), miR-30b-5p mimic + DDP and miR-30b-5p mimic + overexpressed RAP1B + DDP groups. Reverse transcription-quantitative PCR (RT-qPCR) demonstrated significantly lower miR-30b-5p expression in MDA-MB-231 compared with MCF-10A normal breast epithelial cells (P<0.001), which was rescued by miR-30b-5p mimics. Cell Counting Kit-8 assays revealed that miR-30b-5p overexpression or DDP alone suppressed cell viability (P<0.001), with combined treatment showing synergistic inhibition (P<0.001). Flow cytometry demonstrated increased apoptosis in miR-30b-5p mimic and DDP groups, further amplified by their combination (P<0.001). Luciferase reporter and RNA pull-down-qPCR assays confirmed miR-30b-5p directly targets RAP1B 3'-untranslated region (UTR) via sequence-specific binding. RNA pull-down demonstrated molecular association between miR-30b-5p and RAP1B mRNA, while the luciferase reporter assay confirmed 3'-UTR-specific interaction. Western blotting and RT-qPCR showed miR-30b-5p mimics downregulated RAP1B (P<0.001), reversed by RAP1B overexpression. In the rescue experiment, RAP1B overexpression partially reversed the pro-apoptotic effect of miR-30b-5p under cisplatin treatment, supporting the hypothesis that RAP1B mediates the effect of miR-30b-5p on the cisplatin response (P<0.001). These findings indicate that miR-30b-5p potentiates cisplatin-induced cytotoxicity in TNBC by suppressing RAP1B, suggesting a novel therapeutic strategy to overcome chemoresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.